Middle East & Africa T-cell Therapy Market Size & Outlook
Middle East & Africa t-cell therapy market, 2018-2028 (US$M)
Related Markets
MEA t-cell therapy market highlights
- The MEA t-cell therapy market generated a revenue of USD 131.8 million in 2021.
- The market is expected to grow at a CAGR of 8.9% from 2022 to 2028.
- In terms of segment, commercialized was the largest revenue generating modality type in 2021.
- Commercialized is the most lucrative modality type segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2022 to 2028.
MEA data book summary
| Market revenue in 2021 | USD 131.8 million |
| Market revenue in 2028 | USD 238.8 million |
| Growth rate | 8.9% (CAGR from 2021 to 2028) |
| Largest segment | Commercialized |
| Fastest growing segment | Commercialized |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Commercialized |
| Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.1% of the global t-cell therapy market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2028.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,113.5 million by 2028.
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
T-cell Therapy Market Scope
T-cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa t-cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 100% in 2021. Horizon Databook has segmented the Middle East & Africa t-cell therapy market based on commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
The MEA region consists of countries such as South Africa and Saudi Arabia. According to WHO, noncommunicable diseases and injuries account for 49% of the deaths in South Africa. Various initiatives have been undertaken by the government to reduce the incidence of these diseases.
For instance, National Health Promotion Foundation in South Africa monitors the prevalence and suggests measures to reduce the incidence. Growing healthcare awareness, increasing penetration of health insurance, and privatization are some of the factors anticipated to fuel market growth in this region.
Reasons to subscribe to Middle East & Africa t-cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa t-cell therapy market databook
-
Our clientele includes a mix of t-cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa t-cell therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
MEA t cell therapy market size, by country, 2018-2028 (US$M)
Middle East & Africa T-cell Therapy Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
